«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2015年第1期

页码:

110-114,117

栏目:

综述

出版日期:

2014-09-25

文章信息/Info

Title:

Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation

作者:

龙 毅; 刘 凡

(重庆市中医院心血管内科，重庆 400011)

Author(s):

LONG Yi;  LIU Fan

(Department of Cardiology, Hospital of Traditional Chinese Medicine, Chongqing 400011, China)

关键词:

达比加群酯; 心房颤动; 射频消融; 围手术期; 抗凝

Keywords:

dabigatran;  atrial fibrillation;  ablation;  periprocedural;  anticoagulation

分类号:

R541.75

DOI:

-

文献标识码:

A

摘要:

达比加群酯已被批准用于预防非瓣膜性房颤(atrial fibrillation,AF)的卒中及体循环栓塞。然而在AF导管消融围手术期使用达比加群酯的有效性和安全性并未得到充分的研究，本文旨在评估达比加群酯用于AF射频消融围手术期的有效性和安全性。

Abstract:

Dabigatran was approved for the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). However, the safety and efficacy of dabigatran for periprocedural anticoagulation in the setting of AF ablation are not well studied. This article reviews the safety and effectiveness of periprocedural dabigatran for anticoagulation in patients undergoing AF ablation.

参考文献/References

[1]Poli D,Antonucci E,Grifoni E,et al.Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention[J].Thromb Haemost,2009,101(2):367-372.
[2]Fuster V,Rydén LE,Cannom DS,et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidel[J].Circulation,2011,123(10):e269-e367.
[3]Cappato R,Calkins H,Chen SA,et al.Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation[J].Circ Arrhythm Electrophysiol,2010,3(1):32-38.
[4]Calkins H,Brugada J,Packer DL,et al.HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation:recommendations for personnel,policy,procedures and follow-up[J].Europace,2007,9(6):335-379.
[5]Cappato R,Calkins H,Chen SA,et al.Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation[J].Circulation,2005,111(9):1100-1105.
[6]Dixit S,Marchlinski FE.How to recognize, manage, and prevent complications during atrial fibrillation ablation[J].Heart Rhythm,2007,4(1):108-115.
[7]Vazquez SR,Johnson SA,Rondina MT.Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation[J].Thromb Res,2010,126(2):e69-e77.
[8]Viles-Gonzalez JF,Mehta D.Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation［J］. Curr Cardiol Rep,2011,13(1):38-42.
[9]Takahashi A,Kuwahara T,Takahashi Y.Complications in the catheter ablation of atrial fibrillation:incidence and management[J].Circ J,2009,73(2):221-226.
[10]Hussein AA,Martin DO,Saliba W,et al.Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio:a safe and efficacious periprocedural anticoagulation strategy[J].Heart Rhythm,2009 6(10):1425-1429.
[11]Winkle RA,Mead RH,Engel G,et al.Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation[J].Am Heart J,2011,162(1):193-200.
[12]Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[13]Beasley BN,Unger EF,Temple R.Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran[J].N Engl J Med,2011,364(19):1788-1790.
[14]Lakkireddy D,Reddy YM,Di Biase L,et al.Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry[J].J Am Coll Cardiol,2012, 59(13):1168-1174.
[15]Walenga JM,Adiguzel C.Drug and dietary interactions of the new and emerging oral anticoagulants[J].Int J Clin Pract,2010,64(7):956-967.
[16]Stangier J,Eriksson BI,Dahl OE,et al.Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement[J].J Clin Pharmacol,2005,45(5):555-563.
[17]Kaseno K,Naito S,Nakamura K,et al.Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation[J].Circ J,2012,76(10):2337-2342.
[18]Maddox W,Kay GN,Yamada T,et al.Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation[J].J Cardiovasc Electrophysiol,2013,24(8):861-865.
[19]Winkle RA,Mead RH,Engel G,et al.The use of dabigatran immediately after atrial fibrillation ablation[J].J Cardiovasc Electrophysiol,2012,23(3):264-268.
[20]Imamura K,Yoshida A,Takei A,et al.Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy,safety, and impact on duration of hospital stay[J].J Interv Card Electrophysiol,2013,37(3):223-231.
[21]Konduru SV,Cheema AA,Jones P,et al.Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin[J].J Interv Card Electrophysiol,2012,35(3):277-284.
[22]Kim JS,She F,Jongnarangsin K,et al.Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation[J].Heart Rhythm,2013,10(4):483-489.
[23]Bassiouny M,Saliba W,Rickard J,et al.Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation[J].Circ Arrhythm Electrophysiol,2013,6(3):460-466.
[24]Yamaji H,Murakami T,Hina K,et al.Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation[J].Clin Drug Investig,2013,33(6):409-418.
[25]Snipelisky D,Kauffman C,Prussak K,et al.A comparison of bleeding complications post-ablation between warfarin and dabigatran[J].J Interv Card Electrophysiol,2012,35(1):29-33.
[26]van Ryn J,Stangier J,Haertter S,et al.Dabigatran etexilate--a novel,reversible, oral direct thrombin inhibitor:interpretation of coagulation assays and reversal of anticoagulant activity[J].Thromb Haemost,2010,103(6):1116-1127.
[27]Providência R,Albenque JP, Combes S,et al.Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation:a systematic review and meta-analysis[J].Heart,2014,100(4):324-335.

备注/Memo

备注/Memo:

收稿日期：2014-01-13.
作者简介：龙毅，住院医师，硕士Email：yilong6190@sina.com

常用功能

更新日期/Last Update: 2015-01-20